Skip to main content

Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.

Publication ,  Journal Article
Deppen, SA; Liu, E; Blume, JD; Clanton, J; Shi, C; Jones-Jackson, LB; Lakhani, V; Baum, RP; Berlin, J; Smith, GT; Graham, M; Sandler, MP ...
Published in: J Nucl Med
May 2016

UNLABELLED: Our purpose was to evaluate the safety and efficacy of (68)Ga-DOTATATE PET/CT compared with (111)In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and gastroenteropancreatic neuroendocrine tumors. METHODS: (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were obtained for 78 of 97 consecutively enrolled patients with known or suspected pulmonary or gastroenteropancreatic neuroendocrine tumors. Safety and toxicity were measured by comparing vital signs, serum chemistry values, or acquisition-related medical complications before and after (68)Ga-DOTATATE injection. Added value was determined by changes in treatment plan when (68)Ga-DOTATATE PET/CT results were added to all prior imaging, including (111)In-pentetreotide. Interobserver reproducibility of (68)Ga-DOTATATE PET/CT scan interpretation was measured between blinded and nonblinded interpreters. RESULTS: (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were significantly different in impact on treatment (P < 0.001). (68)Ga-DOTATATE PET/CT combined with CT or liver MRI changed care in 28 of 78 (36%) patients. Interobserver agreement between blinded and nonblinded interpreters was high. No participant had a trial-related event requiring treatment. Mild, transient events were tachycardia in 1, alanine transaminase elevation in 1, and hyperglycemia in 2 participants. No clinically significant arrhythmias occurred. (68)Ga-DOTATATE PET/CT correctly identified 3 patients for peptide-receptor radiotherapy incorrectly classified by (111)In-pentetreotide. CONCLUSION: (68)Ga-DOTATATE PET/CT was equivalent or superior to (111)In-pentetreotide imaging in all 78 patients. No adverse events requiring treatment were observed. (68)Ga-DOTATATE PET/CT changed treatment in 36% of participants. Given the lack of significant toxicity, lower radiation exposure, and improved accuracy compared with (111)In-pentetreotide, (68)Ga-DOTATATE imaging should be used instead of (111)In-pentetreotide imaging where available.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Nucl Med

DOI

EISSN

1535-5667

Publication Date

May 2016

Volume

57

Issue

5

Start / End Page

708 / 714

Location

United States

Related Subject Headings

  • Stomach Neoplasms
  • Somatostatin
  • Safety
  • Positron Emission Tomography Computed Tomography
  • Pancreatic Neoplasms
  • Organometallic Compounds
  • Observer Variation
  • Nuclear Medicine & Medical Imaging
  • Neuroendocrine Tumors
  • Neoplasm Staging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Deppen, S. A., Liu, E., Blume, J. D., Clanton, J., Shi, C., Jones-Jackson, L. B., … Walker, R. C. (2016). Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med, 57(5), 708–714. https://doi.org/10.2967/jnumed.115.163865
Deppen, Stephen A., Eric Liu, Jeffrey D. Blume, Jeffrey Clanton, Chanjuan Shi, Laurie B. Jones-Jackson, Vipul Lakhani, et al. “Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.J Nucl Med 57, no. 5 (May 2016): 708–14. https://doi.org/10.2967/jnumed.115.163865.
Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med. 2016 May;57(5):708–14.
Deppen, Stephen A., et al. “Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.J Nucl Med, vol. 57, no. 5, May 2016, pp. 708–14. Pubmed, doi:10.2967/jnumed.115.163865.
Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med. 2016 May;57(5):708–714.

Published In

J Nucl Med

DOI

EISSN

1535-5667

Publication Date

May 2016

Volume

57

Issue

5

Start / End Page

708 / 714

Location

United States

Related Subject Headings

  • Stomach Neoplasms
  • Somatostatin
  • Safety
  • Positron Emission Tomography Computed Tomography
  • Pancreatic Neoplasms
  • Organometallic Compounds
  • Observer Variation
  • Nuclear Medicine & Medical Imaging
  • Neuroendocrine Tumors
  • Neoplasm Staging